

Regeneca, Inc.  
Form 10-Q  
December 20, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 10-Q**

**X . QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2011**

**. TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

**Commission File Number 000-30237**

**REGENECA, INC.**

(Exact name of issuer as specified in its charter)

**Nevada**  
(State of incorporation)

**88-0467241**  
(I.R.S. Employer Identification No.)

**1 Technology, Suite C515**

**Irvine, CA 92618**

(Address of principal executive offices)

**(800) 690-6958**

Edgar Filing: Regeneca, Inc. - Form 10-Q

(Registrant's telephone number, including area code)

with a copy to:

**Christopher A. Wilson, Esq.**

Wilson, Haglund & Paulsen, P.C.

9110 Irvine Center Drive

Irvine, CA 92618

Telephone: (949) 752-1100 ext. 302

Facsimile (949) 752-1144

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  . No  .

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  .

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  . Accelerated filer  .  
Non-accelerated filer  . (Do not check if a smaller reportingSmaller reporting company  .  
company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  
Yes  . No  .

Edgar Filing: Regeneca, Inc. - Form 10-Q

As of September 30, 2011, (the last day of the fiscal quarter to which this report relates), there were 928,590,209 common shares of the registrant's \$.0001 par value common stock issued and outstanding, and as of December 20, 2011 (the latest practical date) there were 875,999,590 common shares outstanding.

---

**REGENECA, INC.**

**TABLE OF CONTENTS**

	<b>Page</b>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	<b>3</b>
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	3
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	14
ITEM 3. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK	16
ITEM 4. CONTROLS AND PROCEDURES	16
<b><u>PART II. OTHER INFORMATION</u></b>	<b>17</b>
ITEM 1. LEGAL PROCEEDINGS	17
ITEM 1A. RISK FACTORS	17
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	17
ITEM 3. DEFAULTS UPON SENIOR SECURITIES	18
ITEM 4. [REMOVED AND RESERVED]	18
ITEM 5. OTHER INFORMATION	18
ITEM 6. EXHIBITS	18

**PART I - FINANCIAL INFORMATION**

**ITEM 1.**

**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

	Index
Condensed Consolidated Balance Sheets	4
Condensed Consolidated Statements of Operations	5
Condensed Consolidated Statements of Cash Flows	6
Notes to the Condensed Consolidated Financial Statements	7

**REGENECA, INC.****Condensed Consolidated Balance Sheets**

	<b>September 30,</b>	
	<b>2011</b>	<b>December 31,</b>
	(unaudited)	<b>2010</b>
<b>ASSETS</b>		
<b>Current assets</b>		
Cash	\$ 453,504	\$ 216,476
Accounts receivable	46,748	1,982
Inventory	269,664	129,541
Prepaid license fee	222,638	102,638
Other current assets	279,249	8,027
<b>Total current assets</b>	<b>1,271,803</b>	<b>458,664</b>
<b>Prepaid license fee</b> long-term	482,493	96,568
<b>Furniture and equipment, net</b>	7,525	6,302
<b>Other assets</b>	75,000	
<b>Total assets</b>	<b>\$ 1,836,821</b>	<b>\$ 561,534</b>
<b>LIABILITIES AND STOCKHOLDERS DEFICIT</b>		
<b>Current liabilities</b>		
Accounts payable	\$ 731,902	\$ 208,902
Accrued liabilities	620,599	26,498
Convertible notes payable, net of discounts	1,134,787	204,717
Derivative liabilities	332,203	108,576
Advances payable to related parties	212,362	180,555
<b>Total current liabilities</b>	<b>3,031,853</b>	<b>729,248</b>
<b>Commitments and contingencies (note 8)</b>		
<b>Stockholders deficit:</b>		
Common stock, \$0.0001 par value; 1,900,000,000 and 1,000,000,000 common shares authorized, 928,590,209 and 824,444,037 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively	92,859	82,444
Additional paid-in capital	5,484,196	3,172,151
Accumulated deficit	(6,772,087)	(3,422,309)
<b>Total stockholders deficit</b>	<b>(1,195,032)</b>	<b>(167,714)</b>

<b>Total liabilities and stockholders equity</b>	<b>\$</b>	<b>1,836,821</b>	<b>\$</b>	<b>561,534</b>
--------------------------------------------------	-----------	------------------	-----------	----------------

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

**REGENECA, INC.****Condensed Consolidated Statements of Operations**

(unaudited)

	<b>For the three months ended</b>		<b>For the nine months ended</b>	
	<b>September</b>	<b>September</b>	<b>September</b>	<b>September</b>
	<b>30,</b>	<b>30,</b>	<b>30,</b>	<b>30,</b>
	<b>2011</b>	<b>2010</b>	<b>2011</b>	<b>2010</b>
Revenue	\$ 403,700	\$ 13,474	\$ 2,475,536	\$ 82,456
Cost of sales	69,183	1,469	572,335	9,471
<b>Gross profit</b>	<b>334,517</b>	<b>12,005</b>	<b>1,903,201</b>	<b>72,985</b>
<b>Operating expenses</b>				
Depreciation and amortization expenses	43,485	26,451	96,081	79,186
Selling, general and administrative expenses	1,136,607	474,992	5,453,096	895,190
<b>Total operating expenses</b>	<b>1,180,092</b>	<b>501,443</b>	<b>5,549,177</b>	<b>974,376</b>
<b>Loss from operations</b>	<b>(845,575)</b>	<b>(489,438)</b>	<b>(3,645,976)</b>	<b>(901,391)</b>
<b>Other (income) expenses</b>				
Change in fair value of derivative liabilities	(702,503)		(1,395,013)	
Loss on disposal of assets			5,511	
Interest	745,328	1,510	1,093,304	2,317
	42,825	1,510	(296,198)	2,317
<b>Net loss before income taxes</b>	<b>(888,400)</b>	<b>(490,948)</b>	<b>(3,349,778)</b>	<b>(903,708)</b>
<b>Income taxes</b>				
<b>Net loss</b>	<b>\$ (888,400)</b>	<b>\$ (490,948)</b>	<b>\$ (3,349,778)</b>	<b>\$ (903,708)</b>
<b>Basic and diluted loss per common share</b>				
Basic and diluted	\$ (0.00)	\$ (0.00)	\$ (0.00)	\$ (0.00)
Weighted average common shares outstanding - basic and diluted	881,658,244	312,594,322	855,473,739	223,209,712

*The accompanying notes are an integral part of these condensed consolidated financial statements.*





**REGENECA, INC.****Condensed Consolidated Statements of Cash Flows**

(unaudited)

	<b>For the nine months ended</b>	
	<b>September 30, 2011</b>	<b>September 30, 2010</b>
<b>Cash flows from operating activities</b>		
Net loss	\$ (3,349,778)	\$ (903,708)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	246,081	79,186
Change in estimated fair value of derivative liabilities	(1,395,013)	
Amortization of debt discount	946,546	
Loss on disposal of asset	5,511	
Fair value of stock issued for services	100,000	683,288
Fair value of stock issued for conversion of interest payable	30,878	
Stock based compensation	106,245	
Changes in operating assets and liabilities:		
Accounts receivable	(44,766)	(703)
Inventories	(140,123)	(130,517)
Other current assets	(46,222)	29,498
Accounts payable	523,000	71,930
Accrued liabilities	594,101	4,186
Advances payable to related parties	31,807	93,684
<b>Net cash used in operating activities</b>	<b>(2,391,733)</b>	<b>(73,156)</b>
<b>Cash flows from investing activities</b>		
Purchases of furniture and equipment	(8,739)	(2,500)
<b>Net cash used in investing activities</b>	<b>(8,739)</b>	<b>(2,500)</b>
<b>Cash flows from financing activities</b>		
Proceeds from issuance of convertible debentures	2,537,500	125,000
Net proceeds from sale of common stock for cash	100,000	3,550
<b>Net cash provided by financing activities</b>	<b>2,637,500</b>	<b>128,550</b>
<b>Net increase in cash</b>	<b>237,028</b>	<b>52,894</b>
<b>Cash beginning of period</b>	<b>216,476</b>	<b>2,672</b>
<b>Cash end of period</b>	<b>\$ 453,504</b>	<b>\$ 55,566</b>
<b>Supplemental disclosure of cash flow information</b>		
Interest paid during the period	\$ 23,452	\$ 807

**Supplemental schedule of noncash investing and financing activities**

Issuance of common stock in connection with the conversion of convertible notes payable	\$	815,000	\$	
Issuance of common stock in connection with prepaid license fee	\$	600,000	\$	
Issuance of common stock in connection with consulting agreement	\$	450,000	\$	-

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

**REGENECA, INC.**

**Notes to Consolidated Financial Statements**

(unaudited)

**September 30, 2011**

**1.**

**Organization and Business**

Regeneca International, Inc. was formed on January 9, 2009 in Nevada to create and commercialize a family of natural and organic compound infused products designed to help improve health. The Company currently conducts operations primarily in the United States using a Direct Response Network Marketing business model. The Company's primary products are RegenErect, an all-natural male enhancement product, and RegeneSlim, a natural appetite suppressant. Sales are made to the consumer through the Company's website and by independent representatives.

On December 31, 2010, Regeneca International, Inc. merged into a wholly-owned subsidiary of the Company (the Merger), and in which the Company issued to the former stockholders of Regeneca International, Inc. 420,466,494 shares of its common stock such that, immediately after the Merger, Regeneca International, Inc.'s former stockholders owned approximately 51% of the combined post-Merger entity. The Company subsequently changed its name to Regeneca, Inc. The Merger was accounted for as a capital reorganization or a public shell reverse merger, and, as such, the consolidated financial statements reported herein reflect the operations of Regeneca, Inc. within the new capital structure of the Company.

***Going Concern***

The financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company's assets and the satisfaction of its liabilities in the normal course of business. Since inception, the Company has been engaged in obtaining financing, recruiting personnel, establishing office facilities and developing its sales and marketing strategy.

The Company does not have sufficient cash on hand to fund its administrative and other operating expenses or its proposed sales and marketing programs for the next twelve months. In 2011 through the date of this report, the Company issued \$2,992,500 in convertible notes payable and issued common stock for \$150,000 in cash to fund operations. The Company's ability to become a profitable operating company is dependent upon obtaining financing adequate to fulfill its market introduction activities, and achieving a level of revenues adequate to support the Company's cost structure. Management intends to finance the Company's operations from loans and advances from

current stockholders, future public and private debt and equity offerings and proceeds from product sales. However, there can be no assurance that additional capital will be available, which may affect the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

### ***Risks and Uncertainties***

The Company's research and development activities and the manufacturing and marketing of the Company's products may be subject to the laws, regulations and guidelines, and, in some cases, regulatory approvals, of governmental authorities in the United States and other countries in which the Company's products are or will be marketed. Specifically, in the United States, the Food and Drug Administration (the "FDA") regulates, among other areas, new drug and cosmetic product approvals, over the counter drugs and clinical trials of new products and services to establish the proper labeling, safety and efficacy of these products and services and the accuracy of certain marketing claims.

On May 27, 2011, the Company received a warning letter from the FDA dated May 25, 2011 (the "Warning Letter"). The Warning Letter asserts that the FDA tested lots of the Company's dietary supplement, RegenErect, and concluded that it contained a pharmaceutical ingredient and is, therefore, subject to regulation as a new prescription drug, requiring FDA approval before introduction and delivery. FDA lab analysis has confirmed the presence of Sulfoildenafil, an analogue of Sildenafil, making these products unapproved new drugs. Sildenafil is an FDA-approved drug used as treatment for male Erectile Dysfunction ("ED"). The active drug ingredient is not listed on the label for these products.

According to the FDA, use of these products may pose a threat to consumers because the analogue may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may lower blood pressure to dangerous levels. FDA has advised that consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. FDA has advised that ED is a common problem in men with these conditions, and consumers may seek these types of products to enhance sexual performance.

The FDA also asserts that, because it is a new prescription drug, RegenErect is misbranded as a dietary supplement, and that the advertising and promotional claims of the Company exceed the claims permitted for dietary supplements. The Warning Letter required the Company to respond within 15 days, disclosing the specific steps taken to correct the alleged violations. The Company responded to the Warning Letter and also undertook a voluntary national recall of certain lots of the Company's RegenErect product.

If unresolved, the claims in the Warning Letter would have a substantial impact on the Company's ability to market and sell RegenErect and would materially affect the business, operations and financial condition of the Company. However, the Company believes that it can adequately address all of the FDA's concerns without a material impact on the Company's business. Nonetheless, the Company cannot give any assurance that the FDA will be satisfied with the Company's response or remedial plan and cannot estimate the date on which these concerns will be resolved, if ever.

2.

### **Summary of Significant Accounting Policies**

a)

#### **Basis of Presentation and Principles of Consolidation**

These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated.

b)

#### **Interim Financial Statements**

These interim unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and in accordance with the instructions of the Securities and Exchange Commission (SEC) for Form 10-Q. They do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended December 31, 2010 filed with the SEC on Form 10-K. The condensed consolidated balance sheet as of December 31, 2010 has been derived from the audited consolidated financial statements contained in the annual report on Form 10-K for the year ended December 31, 2010.

The condensed consolidated financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company's financial position, and the results of its operations and cash flows. The results of operations for the period ended September 30, 2011 are not necessarily indicative of the results to be expected for future quarters or the full year.

c)

#### **Use of Estimates**

The preparation of these unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to valuation allowances on accounts receivable and inventory, valuation and amortization policies on property and equipment, and valuation allowances on deferred income tax losses. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company's estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

d)

#### **Cash Equivalents**

The Company considers all highly liquid short-term investments with maturities of less than three months when acquired to be cash equivalents. The Company had no cash equivalents at September 30, 2011 and December 31, 2010.

e)

#### **Concentration of Credit Risk and Off-Balance Sheet Risk**

The Company has no material concentrations of credit risk, nor is it a party to any financial instruments with material off-balance sheet risk. Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company places its cash with major financial institutions.





Reserves for uncollectible amounts are provided, based on past experience and a specific analysis of the accounts. Management determined there was no such allowance necessary at September 30, 2011.

f)

#### **Inventory**

At September 30, 2011 and December 31, 2010, inventory consisted of finished goods and is stated at the lower of cost or market. Cost is based on the first in, first out method. The Company regularly reviews inventory quantities on hand and, when required, provisions are made to reduce excess and obsolete inventories to their estimated net realizable value. No such provision was recorded in the nine months ended September 30, 2011 or 2010.

g)

#### **Revenue Recognition and Accounts Receivable**

Sales primarily represent sales generated to consumers and independent representatives less any discounts and other deductions. The Company recognizes revenue upon delivery, when both title and the risks and rewards of ownership pass to the independent representatives. More specifically, the Company recognizes revenues when all of the following conditions exist: a) persuasive evidence of an arrangement exists in the form of an accepted purchase order; b) delivery has occurred, based on shipping terms, or services have been rendered; c) the Company's price to the buyer is fixed or determinable, as documented on the accepted purchase order; and d) collectibility is reasonably assured. The Company provides for an estimated allowance for sales returns based on historical product return experience.

Other revenue represents shipping and handling fees billed to consumers and independent representatives.

h)

#### **Stock-based Compensation**

The Company records stock-based compensation in accordance with ASC 718, Share-Based Payments, using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments

issued.

i)

### **Derivative Instruments**

The Company evaluates free-standing derivative instruments (or embedded derivatives) to properly classify such instruments within equity or liabilities in our consolidated financial statements.

The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified.

Instruments classified as derivative liabilities are remeasured each reporting period (or upon classification) and the change in fair value is recorded on our consolidated statement of operations in other (income) expense.

j)

### **Beneficial Conversion Feature of Convertible Notes Payable**

The convertible feature of certain notes payable provides for a rate of conversion that is below market value. Such feature is normally characterized as a "Beneficial Conversion Feature" ("BCF"). We measure the estimated fair value of the BCF in circumstances in which the conversion feature is not required to be separated from the host instrument and accounted for separately, and record that value in the consolidated financial statements as a discount from the face amount of the notes. Such discounts are amortized to interest expense over the term of the notes.

k)

### **Basic and Diluted Loss Per Common Share**

Basic loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per common share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method if their effect is dilutive. For all periods presented, the effects of all stock-based awards were anti-dilutive due to the net loss incurred and therefore, they were not included in the

computation of per share amounts. At September 30, 2011 and December 31, 2010, there were 30,000,000 options to acquire shares of common stock outstanding.

**3.**

**License Agreement**

In December 2009, the Company entered into a license agreement with Vivakor, Inc. ( Vivakor ), a publicly traded company and related party by way of common executive officers, whereby the Company has been granted exclusive worldwide distribution rights to Vivakor's VivaBoost nutraceutical beverage in the direct-to-consumer market. The Company has agreed to purchase \$5,000,000 in product over the initial thirty-six month term and, in the event specified purchase milestones are not met during the initial thirty-six month term, Vivakor has the option to modify or terminate the agreement upon 60 days notice. Upon execution of the license agreement, the Company issued to Vivakor 22,734,236 of its common shares, which were valued at \$307,915 and recorded as a prepaid license fee. The prepaid license fee is being expensed on a straight-line basis over the initial thirty-six month term of the license agreement. For the three months and nine months ended September 30, 2011 and 2010, the Company recognized amortization expense of \$25,660 and \$76,980, respectively, which decreased the carrying value of the license to a net total of \$122,227 (\$102,638 short-term and \$19,589 long-term) at September 30, 2011.

In August 2011, the Company entered into an employment agreement with Dr. Shirish Phulgaonkar whereby Dr. Phulgaonkar would create for the Company a male pro-health formula and a female pro-health formula. The Company will retain the permanent license to these product formulations dependant on attaining sales of 5,000,000 units in the first eighteen months of the agreement. In connection with the development of these formulas, the Company issued Dr. Phulgaonkar 30,000,000 of its common shares, which were valued at \$600,000 based on the Company's common stock trading price at time of issuance, and recorded as a prepaid license fee. The prepaid license fee is being expensed on a straight-line basis over the estimated useful life of the product of five years, subject to any required review for impairment. For the three months ended September 30, 2011, the Company recognized amortization expense of \$17,096, which decreased the carrying value of the license to a net total of \$582,904 (\$120,000 short-term and \$462,904 long-term) at September 30, 2011.

**4.**

**Other Assets**

In February 2011, the Company entered into a two-year agreement with Goal Capital for investor relations consulting services. In connection with the agreement, ten million shares of the Company's common stock were issued to Goal Capital. The shares were valued at a total of \$450,000 based on the current stock price of \$0.045 per share which was recorded as a prepaid asset. In the three months and nine months ended September 30, 2011, \$56,250 and \$150,000 was recorded as compensation expense, respectively, which decreased the carrying value of the prepaid asset to \$300,000 at September 30, 2011.

**5.**

## Convertible Notes Payable

In the three months ended March 31, 2011, the Company issued \$1,122,500 of convertible promissory notes. Under the terms of the note agreements, each note is due interest at 12% per annum, secured by the Company's assets, due in two years from the date of issuance. The notes, along with any accrued interest, shall be convertible into common shares of the Company at the option of the note holder at the lesser of 1) \$0.025 per share or 2) 90% of such common stock's fair market value. The notes contain "anti-dilution" protection, such that if the Company issues and sells common stock, or securities convertible into or exercisable for common stock of the Company, at a price per share that is less than the applicable Conversion Price, then the Conversion Price is adjusted downward to match such lower issuance price. On these notes, a debt discount was recorded of approximately \$905,500 related to management's determination that under ASC 815, the anti-dilution features of the notes resulted in a derivative liability. Using a binomial lattice valuation model, management determined that the derivative fair value was \$905,500 upon issuance of such notes. Accordingly, management recorded a liability of \$905,500 and a debt discount of equal amount.

In the three months ended June 30, 2011, the Company issued \$1,015,000 of convertible promissory notes. Under the terms of the note agreements, each note is due interest at 12% per annum, secured by the Company's assets, due in two years from the date of issuance. The notes, along with any accrued interest, shall be convertible into common shares of the Company at the option of the note holder at the lesser of 1) \$0.025 per share or 2) 90% of such common stock's fair market value. The notes contain "anti-dilution" protection, such that if the Company issues and sells common stock, or securities convertible into or exercisable for common stock of the Company, at a price per share that is less than the applicable Conversion Price, then the Conversion Price is adjusted downward to match such lower issuance price. On these notes, a debt discount was recorded of approximately \$763,500 related to management's determination that under ASC 815, the anti-dilution features of the notes resulted in a derivative liability. Using a binomial lattice valuation model, management determined that the derivative fair value was \$763,500 upon issuance of such notes. Accordingly, management recorded a liability of \$763,500 and a debt discount of equal amount.

In the three months ended September 30, 2011, the Company issued \$400,000 of convertible promissory notes. Under the terms of the note agreements, each note is due interest at 8% per annum, secured by the Company's assets, due in two years from the date of issuance. The notes, along with any accrued interest, shall be convertible into common shares of the Company at the option of the note holder at the lesser of 1) \$0.025 per share or 2) 90% of such common stock's fair market value. The notes contain "anti-dilution" protection, such that if the Company issues and sells common stock, or securities convertible into or exercisable for common stock of the Company, at a price per share that is less than the applicable Conversion Price, then the Conversion Price is adjusted downward to match such lower issuance price. On these notes, a debt discount was recorded of approximately \$70,000 related to management's determination that under ASC 815, the anti-dilution features of the notes resulted in a derivative liability. Using a binomial lattice valuation model, management determined that the derivative fair value was \$70,000 upon issuance of such notes. Accordingly, management recorded a liability of \$70,000 and a debt discount of equal amount.

Significant assumptions used in such valuation include:

	Three months ended
	September 30, 2011
Expected life	2 years
Estimated volatility	35.07%
Risk-free interest rate	0.18% 0.37%
Expected dividends	None

In the three months and nine months ended September 30, 2011, the Company recognized interest expense of \$679,248 and \$946,546, respectively, related to such notes. The balance of convertible notes payable is shown net of unamortized discounts in the accompanying condensed consolidated balance sheet.

Below is a table summarizing the Company's balances as of September 30, 2011 related to its convertible notes payable:

	Issue Date	Face Amount	Unamortized Discount	Net Amount	Fair Value of Convertible Option	Derivative Value
1)	12/20/2010	\$120,000	\$33,685	\$86,315		\$18,895
2)	12/29/2010	130,000	37,175	92,825		20,725
3)	1/28/2011	100,000	45,377	54,623		15,180
4)	2/9/2011	75,000	39,393	35,607		11,598
5)	2/23/2011	375,000	224,302	150,698		59,034
6)	3/9/2011	72,500	36,510	35,990		11,589
7)	3/11/2011	25,000	14,779	10,221		4,004
8)	3/16/2011	200,000	118,243	81,757		32,194
9)	4/7/2011	150,000	119,296	30,704		21,235

Edgar Filing: Regeneca, Inc. - Form 10-Q

10)	4/22/2011	100,000	56,815	43,185	15,218
11)	5/18/2011	325,000	145,934	179,066	53,108
12)	7/15/2011	50,000	7,294	42,706	8,064
13)	8/16/2011	100,000	15,627	84,373	17,257
14)	8/23/2011	100,000	18,152	81,848	17,439
15)	8/31/2011	100,000	17,073	82,927	17,632
16)	9/20/2011	50,000	8,058	41,942	9,031
		\$2,072,500	\$937,713	\$1,134,787	\$332,203

During the three months ended September 30, 2011, \$815,000 of convertible notes payable principal and \$30,878 of accrued interest was converted into 45,731,617 common shares of the Company.

For the three and nine months ended September 30, 2011, the change in the estimated fair value of derivative liability resulted in a gain of \$702,503 and \$1,395,013, respectively, and is included in other income in the accompanying condensed consolidated statements of operations.

**6.**

**Advances Payable to Related Parties**

Advances payable to related parties are noninterest bearing and represent cash advances directly to the Company as well as Company expenditures that were paid for directly by the related parties on behalf of the Company for which the related parties have not been reimbursed. These advances are unsecured and came from directors and officers of the Company.

7.

**Stock Incentive Plan**

On December 31, 2010, the Company adopted the 2010 Stock Incentive Plan, pursuant to which the Company is authorized to issue up to 20% of its outstanding shares of common stock to its employees, executives and consultants. On December 31, 2010, the Company issued certain employees, executives, and consultants 30,000,000 options to purchase Company common stock at \$0.025 per share, with vesting ranging from 2 years to 3 years. At September 30, 2011, there were 212,000,000 shares available for future grants under the plan.

The Company recorded compensation costs related to options granted under the 2010 Incentive Plan of \$35,415 and \$106,245 during the three months and nine months ended September 30, 2011, respectively, and total unrecognized compensation costs related to nonvested options as of September 30, 2011 amounted to \$263,755 and, assuming the grantees continue to be employed by or remain as directors of the Company, such amount will be recognized as compensation expense as follows:

Years ending December 31,		
2011 (remainder of year)	\$	35,422
2012		141,667
2013		86,666
	\$	263,755

There was no stock option activity during the nine months ended September 30, 2011.

8.

**Commitments and Contingencies***Operating Leases*

The Company leases approximately 8,700 square feet of office space under a lease due to expire on April 30, 2016. Rent expense totaled \$74,806 and \$28,017 in the nine months ended September 30, 2011 and 2010, respectively.



Edgar Filing: Regeneca, Inc. - Form 10-Q

As of September 30, 2011, the Company's future annual minimum lease payments are as follows:

	Amount
2011 (remainder of year)	\$ 23,481
2012	90,448
2013	97,404
2014	102,624
Thereafter	145,452
	\$ 459,409

*Legal*

The Company may be involved from time to time in various claims, lawsuits, disputes with third parties, actions involving allegations or discrimination or breach of contracts actions incidental to the normal course of operations. Other than what is disclosed below, the Company is currently not involved in any such litigation that management believes could have a material adverse effect on its financial position or results of operations.

The Company is presently involved in the following material pending legal proceedings not incidental to the business of the Company:

In March 2009, a lawsuit was filed in the United States District Court, District of Utah, Central Division, against the Company by Republic Bank. The lawsuit alleged that the Company breached the terms of a Lease Agreement involving Mazuma Capital Corp. and the Company. Republic Bank sought monetary damages and return of certain equipment. On February 9, 2011, Summary Judgment was entered in favor of Republic Bank. Subsequently, the Company and Republic Bank finalized the terms of a settlement agreement during the 2nd quarter of 2011. The terms of the settlement are the forfeiture of the security deposit on the lease, the leased property, and payments totaling \$200,000. The Company was indemnified by a group of stockholders against claims originating before the Merger, and as of December 1, 2011 such stockholders have paid approximately \$150,000 and are obligated to make monthly payments of \$8,791 per month per month for six more months. If not paid by such stockholders, the Company would still be obligated to pay Republic Bank and then pursue its claim for indemnification against the stockholders.

In March 2011, a lawsuit was filed in the Superior Court of California, County of San Diego, South County Division against the Company by Frederick Chorney. The lawsuit alleges that the Company breached the terms of a consulting agreement between the Company and Mr. Chorney. Mr. Chorney is seeking monetary damages in the amount of \$150,000. Mr. Chorney has requested a jury trial which is currently in the discovery stage. The Company, based on advice from counsel, cannot provide assurances as to the outcome of this matter.

**9.**

#### **Equity Transactions**

During the nine months ended September 30, 2011, the Company issued 4,000,000 common shares for cash proceeds of \$100,000.

**10.**

#### **Subsequent Events**

Management has evaluated events subsequent to September 30, 2011 through the date that the accompanying condensed consolidated financial statements were filed with the Securities and Exchange Commission for transactions and other events which may require adjustment of and/or disclosure in such financial statements.

In October 2011, the Company issued 2,800,000 common shares with a fair value of \$42,000 in connection with convertible notes payable issued in October 2011, in accordance with the terms of conversion in the notes.

In October 2011, the Company issued 500,000 common shares with a fair value of \$7,500 for services rendered, valued at \$.015 per share based on the Company's common stock trading price at the time of issuance.

In November 2011, the Company issued 3,267,974 common shares for cash proceeds of \$50,000, at \$.015 per share.

In December 2011, Dr. Shirish Phulgaonkar resigned from his position as Chief Scientific Officer of the Company citing personal and health reasons.



## ITEM 2.

### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION OR PLAN OF OPERATION

#### FORWARD-LOOKING STATEMENTS

*This Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) contains forward-looking statements that involve known and unknown risks, significant uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, or implied, by those forward-looking statements. You can identify forward-looking statements by the use of the words may, will, should, could, expects, plans, anticipates, believes, estimates, predicts, intends, potential, proposed, or continue or the negative of those terms. These statements are only predictions. In evaluating these statements, you should consider various factors which may cause our actual results to differ materially from any forward-looking statements. Although we believe that the exceptions reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.*

#### BUSINESS

The Company's business strategy is a hybrid model combining the best of network marketing and direct response marketing. The Company pre-launched its network marketing activities in February 2011 along with the launch of its male enhancement product RegenErect™. The Company launched its direct response marketing activities in the second quarter of 2011, as well as its appetite control product RegeneSlim™. The Company officially launched its entire functional business model, including both network marketing and direct response marketing, in November 2011.

The Company drives customer acquisition through direct response marketing channels, such as television and radio, while concurrently developing a customer base and sales organization that stretches across the United States and, eventually, the globe. The Company's customer acquisition activities support the efforts of the network marketing organization by providing customers and creating brand recognition.

#### *Subsequent Events*

This Quarterly Report on Form 10-Q for the period ended September 30, 2011 is being filed with the Securities and Exchange Commission on or about December 20, 2011. Due to the delay in filing this report, management has evaluated events subsequent to September 30, 2011 and has concluded that no events have occurred that require recognition or disclosure in this report.

## **RESULTS OF OPERATIONS**

### *Operating Revenues*

During the three and nine months ended September 30, 2011, the Company recognized revenues of \$403,700 and \$2,475,536 compared with \$13,474 and \$82,456 for the three and nine months ended September 30, 2010, respectively. The operating revenues are comprised primarily of sales of the Company's RegenErect™ and RegeneSlim™ products. Other components of revenue include freight and service. The increase in revenues is attributable to the change in the Company's business strategy, the introduction of RegenErect and RegeneSlim, and the pre-launch of the Company's networking marketing program in February 2011. Revenues for the three months ended September 30, 2011 were lower than previous quarters due to the discontinuation and subsequent returns of our second formulation of RegenErect in mid-August 2011. The Company began shipment of its new formulation of RegenErect which was developed by Dr. Shirish Phulgaonkar in late September 2011.

### *Operating Expenses and Net Loss*

Operating expenses for the three and nine months ended September 30, 2011 were \$1,180,092 and \$5,549,177 and are comprised of costs associated with general and administrative costs such as staff salaries, consulting, marketing, and legal and accounting, and selling expenses such as marketing and business development, specifically the marketing costs associated with the increased advertising and media expenses surrounding the launch of RegenErect™ and RegeneSlim™ and launch of the Company's direct response marketing program. Operating expenses for the three months ended September 30, 2011 were lower than previous quarters due to the concentration on the development of the Company's new formulation of RegenErect and a reduction in general and marketing expenditures compared with previous quarters.

Operating expenses for the three and nine months ended September 30, 2010 were \$501,443 and \$974,376 and are comprised of costs associated with general and administrative costs such as staff salaries, consulting, marketing, and legal and accounting, and selling expenses such as marketing and business development.

Other expense for the three months ended September 30, 2011 totaled \$42,825. This total includes again recorded for the change in value of the derivative liability associated with the Company's convertible notes payable of \$702,503, as well as the accretion of the related debt discount totaling \$679,248 which was recorded as interest expense.

For the three and nine months ended September 30, 2011, the Company incurred a net loss of \$888,400 and \$3,349,778 compared with a net loss of \$490,948 and \$903,708 for the three and nine months ended September 30, 2010, respectively. The increase in net loss for the nine month period is due to increased marketing expenses related to the introduction of RegenErect™ and RegenSlim™ and the launch of the Company's direct response marketing program. In the three months ended September 30, 2011, the net loss was lower than previous quarters due to a reduction in operating expenses as well as a gain of \$702,503 on the change of value of the derivative liability from the Company's convertible notes payable.

## LIQUIDITY AND CAPITAL RESOURCES

### *Working Capital*

	<u>September 30, 2011</u>	<u>September 30,</u> <u>2010</u>
Current Assets	\$ 1,271,803	\$ 311,667
Current Liabilities	3,031,853	273,535
Working (Deficit) Capital	\$ (1,760,050)	\$ 38,132

### *Cash Flows*

	For the nine months ended	
	<u>September 30, 2011</u>	<u>September 30, 2010</u>
Cash Flows used in Operating Activities	\$ (2,391,733)	\$ (73,156)
Cash Flows used in Investing Activities	(8,739)	(2,500)
Cash Flows from Financing Activities	2,637,500	128,550
Net Increase in Cash During Period	\$ 237,028	\$ 52,894

At September 30, 2011, the Company had cash of \$453,504, current assets of \$1,271,803, total assets of \$1,836,821, total liabilities of \$3,031,853, and a stockholders' deficit of \$1,195,032.

At September 30, 2011, the Company had negative working capital of \$1,760,050 compared with a working capital of \$38,132 at September 30, 2010. The decrease in working capital was attributed to the fact that the Company had higher accrued liabilities due to its expanded operating expenses, as well as liabilities related to its convertible notes payable and derivative liabilities.

#### ***Cash Flows from Operating Activities***

During the nine months ended September 30, 2011, the Company used \$2,391,733 of cash for operating activities compared to the use of \$73,156 of cash from operating activities during the nine months ended September 30, 2010. The change in net cash used in operating activities is attributed to the fact that the Company was launching RegenErect™ and RegeneSlim™ and its network marketing and direct response programs in the nine months ended September 30, 2011.

#### ***Cash Flows from Financing Activities***

During the nine months ended September 30, 2011, the Company received \$2,637,500 of cash from financing activities compared to \$128,550 for the nine months ended September 30, 2010. The change in cash flows from financing activities is attributed to the fact that the Company issued notes payable in the nine months ended September 30, 2011 in order to fund the Company's expanded operations.

### ***Going Concern***

The Company does not have sufficient cash on hand to fund its administrative and other operating expenses or its proposed sales and marketing programs for the next twelve months. During the first nine months of 2011, the Company has issued \$2,587,500 in convertible promissory notes in exchange for cash to fund operations. The Company's ability to become a profitable operating company is dependent upon obtaining financing adequate to fulfill its market introduction activities, and achieving a level of revenues adequate to support the Company's cost structure. Management intends to finance the Company's operations from loans and advances from current stockholders, future public and private debt and equity offerings and proceeds from product sales. However, there can be no assurance that additional capital will be available, which may affect the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

### **OFF-BALANCE SHEET ARRANGEMENT**

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

### **CRITICAL ACCOUNTING POLICIES**

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We believe that the estimates and assumptions that are most important to the portrayal of our financial condition and results of operations, in that they require the most difficult, subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These critical accounting policies relate to beneficial conversion feature of convertible notes payable, impairment of long lived assets, stock compensation, and evaluation of contingencies. We believe estimates and assumptions related to these critical accounting policies are appropriate under the circumstances; however, should future events or occurrences result in unanticipated consequences, there could be a material impact on our future financial condition or results of operations.



There have been no changes to our critical accounting policies as disclosed in our Form 10-K for the year ended December 31, 2010.

**ITEM 3.**

**QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

**ITEM 4.**

**CONTROLS AND PROCEDURES**

*Evaluation of Disclosure Controls and Procedures*

Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management carried out an evaluation under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 ("Exchange Act"). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective based on our material weakness in the form of lack of segregation of duties, which stems from our early stage status and limited capital resources to hire additional financial and administrative staff. Please refer to our Annual Report on Form 10-K as filed with the SEC on December 20, 2011, for a complete discussion relating to the foregoing evaluation of Disclosures and Procedures.

*Changes in Internal Control over Financial Reporting*

Our management has also evaluated our internal control over financial reporting, and there have been no significant changes in our internal controls or in other factors that could significantly affect those controls subsequent to the date of our last evaluation.

**PART II - OTHER INFORMATION**

**ITEM 1.**

**LEGAL PROCEEDINGS.**

From time to time, we are involved in routine legal matters incidental to our business. In the opinion of management, the ultimate resolution of such matters will not have a material adverse effect on our financial position, results of operations or liquidity.

Consistent with Item 103 of Regulation S-K, we are presently involved in the following material pending legal proceedings not incidental to the business of the Company:

In March 2009, a lawsuit was filed in the United States District Court, District of Utah, Central Division, against Ethos Environmental, Inc. by Republic Bank. The lawsuit alleges that the Company breached the terms of a Lease Agreement involving Mazuma Capital Corp. and Ethos. Republic Bank is seeking monetary damages and return of certain equipment. On February 9, 2011, Summary Judgment was entered in favor of Republic Bank. The Company and Republic Bank finalized the terms of a settlement agreement during the 2<sup>nd</sup> quarter of 2011. The terms of the settlement are the forfeiture of the security deposit on the lease, the leased property, and payments totaling \$200,000. The Company was indemnified by a group of shareholders against claims originating prior to the Merger, and as of December 20, 2011 such shareholders have paid approximately \$150,000 and are obligated to make monthly payments of \$8,334 per month plus interest for through June 2012. If not paid by such shareholders, the Company would still be obligated to pay Republic Bank and then pursue its claim for indemnification against the shareholders.

In March 2011, a lawsuit was filed in the Superior Court of California, County of San Diego, South County Division against the Company by Frederick Chorney. The lawsuit alleges that the Company breached the terms of a consulting agreement between the Company and Mr. Chorney. Mr. Chorney is seeking monetary damages in the amount of \$150,000. Mr. Chorney has requested a jury trial which is currently in the discovery stage. The Company, based on advice from council, cannot provide assurances as to the outcome of this matter at this time.

**ITEM 1A.**

**RISK FACTORS**

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

**ITEM 2.**

**UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

**1.**

**Quarterly Issuances:**

In August 2011, the Company issued 30,000,000 common shares with a fair value of \$600,000 pursuant to a license agreement.

In August 2011, the Company issued 5,000,000 common shares with a fair value of \$100,000 for services rendered.

In August 2011, the Company issued 26,842,727 common shares in connection with the conversion of convertible notes payable with a face amount of \$475,000 and accrued interest of \$30,878.

In September 2011, the Company issued 18,888,890 common shares in connection with the conversion of convertible notes payable with a face amount of \$340,000.

**2.**

**Subsequent Issuances:**

Edgar Filing: Regeneca, Inc. - Form 10-Q

In October 2011, the Company issued 2,800,000 common shares with a fair value of \$42,000 in connection with convertible notes payable issued in October 2011, in accordance with the terms of conversion in the notes.

In October 2011, the Company issued 500,000 common shares with a fair value of \$7,500 for services rendered, valued at \$.015 per share based on the Company's common stock trading price at the time of issuance.

In November 2011, the Company issued 3,267,974 common shares for cash proceeds of \$50,000, at \$.015 per share.

In December 2011, Dr. Shirish Phulgaonkar resigned from his position as Chief Scientific Officer of the Company citing personal and health reasons.

**ITEM 3.**

**DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4.**

[REMOVED AND RESERVED]

**ITEM 5.**

**OTHER INFORMATION**

None.

**ITEM 6.**

**EXHIBITS**

The following exhibits are filed with this Quarterly Report on Form 10-Q:

*Index to Exhibits*

<b>Exhibit Number</b>	<b>Description of Exhibit</b>	<b>Filing</b>
3.01	Amended and Restated Articles of Incorporation	Filed with the SEC on May 24, 2011 as part of our Definitive Information Statement on Schedule 14C.
3.02		

Edgar Filing: Regeneca, Inc. - Form 10-Q

	Amended and Restated Bylaws effective as of January 20, 2011	Filed with the SEC on December 20, 2011 as part of our Annual Report on Form 10-K.
10.1	Agreement and Plan of Merger by and among Ethos Environmental, Inc., EEI Acquisition Corporation and Regeneca International, Inc. dated December 14, 2010	Filed with the SEC on January 4, 2011 as part of our Current Report on Form 8-K.
14.1	Code of Ethics	Filed with the SEC on April 15, 2009 as part of our Annual Report on Form 10-K.
16.1	Letter from former independent public accountant for the registrant, M&K CPAS, PLLC, dated September 16, 2011	Filed with the SEC on September 20, 2011 as part of our Current Report on Form 8-K.
21.1	List of Subsidiaries	Filed with the SEC on December 20, 2011 as part of our Annual Report on Form 10-K.
31.01	Certification of Principal Executive Officer Pursuant to Rule 13a-14	Filed herewith.
31.02	Certification of Principal Financial Officer Pursuant to Rule 13a-14	Filed herewith.
32.01	Chief Executive Officer and Chief Financial Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act	Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**REGENECA, INC.**

Dated: December 20, 2011

By:

/s/ Matthew Nicosia

**MATTHEW NICOSIA**

Chief Executive Officer

(Principal Executive Officer),

President and Director

/s/ Daniel Kerker

**DANIEL KERKER**

Chief Financial Officer

(Principal Financial Officer

and Principal Accounting

Officer) and Treasurer